A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. We’re inching closer to having the first-ever needle-free weight loss drug. That’s thanks to Novo Nordisk, which expects a U.S. approval for …
The Eli Lilly headquarters in Indianapolis, Indiana, on Aug. 15, 2024. AJ Mast | Bloomberg | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Eli Lilly‘s closely watched …
Eli Lilly Biotechnology Center is shown in San Diego, California, U.S. March 1, 2023. Mike Blake | Reuters Eli Lilly on Tuesday said its daily weight loss pill helped patients with obesity and Type 2 diabetes shed weight in a late-stage trial, meeting the study’s main goal and clearing the …
Eternalcreative | Istock | Getty Images Miracle drugs, obesity treatments and skinny jabs. Call them what you will, few drugs have had a more transformative effect on Wall Street and waistlines over recent decades than GLP-1s. Familiarly known under the brand names Wegovy and Zepbound, Glucagon-like peptide-1 (GLP-1) receptor agonists are a …
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly‘s stock is still recovering after the drugmaker released trial data earlier this month on its closely watched obesity pill that underwhelmed Wall Street. …
Eli Lilly delivered strong second-quarter results on Thursday, but shares are plummeting because of disappointing data for a key late-stage trial. It’s forcing us to ask ourselves difficult questions about this once-loved stock. Revenue in the three months ended June 30 jumped 38% year over year to $15.56 billion, beating …
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly on Thursday said the highest dose of its daily obesity pill helped patients lose almost 12% of their body weight, or roughly 27 …
Many on Wall Street expect that Novo Nordisk ‘s loss has been Eli Lilly ‘s gain, and this will be good news for the Zepbound maker’s second-quarter results. Novo Nordisk’s stock has cratered about 47% since the start of the year, as doubts emerged about the outlook for its GLP-1 …
A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Hollie Adams | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here …
Wall Street ended a busy week of earnings, economic data and policy decisions with a thud, as a weak jobs report renewed concerns about the health of the U.S. economy in the face of President Donald Trump’s ever-shifting tariff policy. In the week ahead, investors will look to the latest …